Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Multiple Myeloma Research and Treatments, and HER2/EGFR in Cancer Research.
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for<i>HER2 (ERBB2)</i>–Positive Breast Cancer
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> - or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Operative and Therapeutic Advancements in Breast Cancer Metastases to the Brain
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma
Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer
Multiple Myeloma, Version 2.2016
Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway
Breast Cancer Version 3.2014
A cell-intrinsic role for TLR2–MYD88 in intestinal and breast epithelia and oncogenesis
Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
Multiple Myeloma, Version 1.2013
The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma